Magazine Article | November 1, 2016

Clinical Trials In China: A Model For Advancing Cancer Therapies

Source: Life Science Leader

By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical

Increasingly, pharmaceutical and biotechnology companies are enrolling patients in countries outside the U.S. Richard Brand, CFO for BeyondSpring Pharmaceuticals, believes this trend will continue going forward, especially for larger Phase 3 clinical trials.

China, with its considerable population and large number of patients diagnosed with cancer, has been of particular interest for clinical trials where genetic differences between the Chinese and Western populations are not a factor. CROs, consulting companies, and drug development firms that have assisted Chinese drug development companies with clinical trials and the regulatory review process have attracted interest from Western drug development companies, especially those that are seeking to effectively and efficiently navigate the procedures in place in China.